Viracta Therapeutics, Inc., a precision oncology company targeting virus-associated malignancies, announced that Dan Chevallard, Chief Financial Officer of Viracta, will present a company overview at the 2020 BIO CEO and Investor Conference on Tuesday, February 11, 2020 at 2:30 pm ET in New York, NY.
SAN DIEGO, Feb. 4, 2020 /PRNewswire/ -- Viracta Therapeutics, Inc. (the “Company”), a precision oncology company targeting virus-associated malignancies, announced today that Dan Chevallard, Chief Financial Officer of Viracta, will present a company overview at the 2020 BIO CEO and Investor Conference on Tuesday, February 11, 2020 at 2:30 pm ET in New York, NY.
About Viracta Therapeutics, Inc.
Viracta is a precision oncology company targeting virus-associated malignancies. The Company’s proprietary investigational drug, nanatinostat, is currently being evaluated in combination with valganciclovir as an oral combination therapy in a Phase 2 clinical trial for Epstein-Barr virus-associated lymphomas. Viracta is pursuing application of this Kick and Kill treatment approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma, and other viral-related cancers. For additional information please visit www.viracta.com.
Media Contact:
Amy Conrad
Juniper Point
amy@juniper-point.com
858-366-3243
Investor Contact:
Sam Martin
Argot Partners
sam@argotpartners.com
212-600-1902
View original content to download multimedia:http://www.prnewswire.com/news-releases/viracta-therapeutics-to-present-at-the-2020-bio-ceo--investor-conference-300998882.html
SOURCE Viracta Therapeutics, Inc.
